Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siFANCL
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
siFANCL is a small interfering RNA (siRNA) designed to specifically silence the expression of the **FANCL** (Fanconi Anemia Complementarity Group L) gene. FANCL encodes an E3 ubiquitin ligase that is a core component of the Fanconi Anemia (FA) complex, which is essential for the repair of DNA interstrand cross-links. In the context of oncology, particularly hepatocellular carcinoma (HCC), FANCL has been identified as a risk factor associated with poor prognosis and resistance to treatment. By knocking down FANCL, siFANCL inhibits the DNA damage response (DDR) pathway, potentially sensitizing cancer cells to DNA-damaging agents like platinum-based chemotherapy and anthracyclines, and modulating immunogenic cell death (ICD).
- Other names
- FANCL siRNAsiRNA targeting FANCL
02
Targets
FANCL (Fanconi anemia group L protein)
Beyond the preview
Go deeper on siFANCL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siFANCL.